HK1199418A1 - 供持續釋放的活性劑製劑 - Google Patents
供持續釋放的活性劑製劑Info
- Publication number
- HK1199418A1 HK1199418A1 HK14113095.1A HK14113095A HK1199418A1 HK 1199418 A1 HK1199418 A1 HK 1199418A1 HK 14113095 A HK14113095 A HK 14113095A HK 1199418 A1 HK1199418 A1 HK 1199418A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulations
- active agents
- sustained release
- sustained
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526940P | 2011-08-24 | 2011-08-24 | |
US201161551506P | 2011-10-26 | 2011-10-26 | |
PCT/US2012/052304 WO2013028989A1 (en) | 2011-08-24 | 2012-08-24 | Formulations of active agents for sustained release |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1199418A1 true HK1199418A1 (zh) | 2015-07-03 |
Family
ID=47746903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14113095.1A HK1199418A1 (zh) | 2011-08-24 | 2014-12-31 | 供持續釋放的活性劑製劑 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130084277A1 (zh) |
EP (2) | EP4295858A1 (zh) |
JP (1) | JP6169079B2 (zh) |
CN (1) | CN104023784B (zh) |
CA (1) | CA2846209C (zh) |
HK (1) | HK1199418A1 (zh) |
WO (1) | WO2013028989A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
KR20150096433A (ko) | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
ES2818824T3 (es) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10722590B2 (en) | 2014-11-21 | 2020-07-28 | Phasebio Pharmaceuticals, Inc. | ELP fusion proteins for controlled and sustained release |
ES2822598T3 (es) | 2015-02-09 | 2021-05-04 | Phasebio Pharmaceuticals Inc | Métodos y composiciones para tratar enfermedades y trastornos musculares |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
ES2909074T3 (es) | 2016-05-06 | 2022-05-05 | Phasebio Pharmaceuticals Inc | Proteínas de fusión ELP para liberación controlada y sostenida |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
CN101500606B (zh) * | 2005-06-24 | 2013-12-04 | 杜克大学 | 基于热反应生物聚合物的直接药物送递系统 |
WO2007073486A2 (en) * | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US7709227B2 (en) * | 2006-01-04 | 2010-05-04 | Phasebio Pharmaceuticals, Inc. | Multimeric ELP fusion constructs |
CN103230598A (zh) * | 2006-09-06 | 2013-08-07 | 费斯生物制药公司 | 融合肽治疗组合物 |
CN101784263B (zh) * | 2007-06-08 | 2012-11-07 | 贝林格尔.英格海姆国际有限公司 | 奈韦拉平的延长释放制剂 |
ES2672770T3 (es) * | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
EP2307038A4 (en) * | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
US20110288001A1 (en) * | 2008-12-18 | 2011-11-24 | Homayoun Sadeghi | Biologically active proteins activatable by peptidase |
ES2870914T3 (es) * | 2009-08-14 | 2021-10-28 | Phasebio Pharmaceuticals Inc | Péptidos intestinales vasoactivos modificados |
CA2873553C (en) * | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
-
2012
- 2012-08-24 EP EP22213287.0A patent/EP4295858A1/en active Pending
- 2012-08-24 CA CA2846209A patent/CA2846209C/en active Active
- 2012-08-24 WO PCT/US2012/052304 patent/WO2013028989A1/en unknown
- 2012-08-24 EP EP12826427.2A patent/EP2747832A4/en not_active Withdrawn
- 2012-08-24 US US13/594,383 patent/US20130084277A1/en not_active Abandoned
- 2012-08-24 JP JP2014527329A patent/JP6169079B2/ja active Active
- 2012-08-24 CN CN201280052426.0A patent/CN104023784B/zh active Active
-
2013
- 2013-12-06 US US14/099,590 patent/US20140171370A1/en not_active Abandoned
-
2014
- 2014-12-31 HK HK14113095.1A patent/HK1199418A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN104023784A (zh) | 2014-09-03 |
WO2013028989A1 (en) | 2013-02-28 |
CA2846209A1 (en) | 2013-02-28 |
EP2747832A4 (en) | 2015-01-07 |
JP6169079B2 (ja) | 2017-07-26 |
CN104023784B (zh) | 2018-05-25 |
CA2846209C (en) | 2022-04-05 |
US20140171370A1 (en) | 2014-06-19 |
JP2014524480A (ja) | 2014-09-22 |
EP4295858A1 (en) | 2023-12-27 |
US20130084277A1 (en) | 2013-04-04 |
EP2747832A1 (en) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1199418A1 (zh) | 供持續釋放的活性劑製劑 | |
CY2200002T2 (el) | Βιοαποικοδομησιμα λιπιδια για την απελευθερωση δραστικων παραγοντων | |
HRP20180924T1 (hr) | Sastavi za transdermalnu administraciju aktivnih sastojaka | |
HRP20161771T1 (hr) | Formulacije bendamustina | |
IL228984A0 (en) | Preparations and methods for stabilization of active agents | |
EP2785333A4 (en) | AMPHIPATIVE COMPOSITIONS WITH DELAYED RELIEF ON LIPID BASIS | |
EP2790729A4 (en) | PARTICULATE FORMULATIONS WITH DELAYED RELEASE | |
CO6900117A2 (es) | Formulaciones peptídicas de liberación controlada | |
ZA201306016B (en) | Bendamustine formulations | |
ZA201208286B (en) | Use of formulations having insecticidal activity | |
ZA201500137B (en) | Dressing having sustained release of active agents | |
ZA201306643B (en) | Formulation comprising phenylaminopyrimidine derivatives as active agent | |
ZA201308316B (en) | Sustained release paracetamol formulations | |
IL236466A0 (en) | Pharmaceutical composition for the release of active components | |
IL228462B (en) | The film-forming composition for sustained release depends on the ph of an active ingredient | |
ZA201305986B (en) | Improved insecticide formulations | |
EP2699094A4 (en) | TASTE-MASKED FORMULATIONS BY RALTEGRAVIR | |
PL2696845T3 (pl) | System do przedłużonego uwalniania środków kosmetycznych | |
IL226237B (en) | Pharmaceutical preparations for administration of active substances through the skin |